Guggenheim Securities Downgrades Biota Pharmaceuticals To Neutral

Analysts at Guggenheim Securities downgraded Biota Pharmaceuticals

from Buy to Neutral. The target price for Biota Pharmaceuticals has been lowered from $5.00 to $3.00. Biota Pharmaceuticals shares have dropped 41.97% over the past 52 weeks, while the S&P 500 index has gained 12.60% in the same period. Biota Pharmaceuticals' shares dropped 24.61% to close at $2.42 on Friday.